Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

Kunst was ousted from the Seattle-based Aurion after Swiss eye-care giant Alcon acquired a majority interest in the company March 26. He tried buying new skis and golf clubs since the takeover ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO.

GENEVA, March 26, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a ...

Alcon Inc.'s strong growth, strategic acquisitions, and market leadership highlight its long-term potential. Read more on ALC ...

Alcon (ALC) “announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases. Aurion will operate as a ...

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

Fast-tracked cross-appeals in Delaware by Alcon Research LLC and Aurion Biotech Inc. have been closed, now that Alcon has bought a majority stake in the company that’s developing a potentially ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech ...

With this move, Alcon aims to expedite the development of Aurion’s cell therapy asset, AURN001, into Phase 3 trials in the U.S. during the second half of 2025. AURN001 has garnered Breakthrough ...

Leverages Alcon’s global scale with Aurion’s cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion’s lead asset received Breakthrough Therapy Designation and ...